CTI Clinical Trial and Consulting Services
(CTI), a global, privately held, full-service contract research organization announces the acquisition of
S2 Statistical Solutions
(S2). S2, a health outcomes and health economics organization, focuses on the power of analytics through data mining and economic research. S2 specializes in generating and interpreting evidence from large databases and then publishing it in the most effective, high-impact venues, including various peer reviewed publications. S2 has been partnering with pharmaceutical, medical device, and diagnostic companies for over a decade, providing innovative outcome and economic analyses, models, visualization programs, systematic literature reviews, and meta analyses. Dr. Candace Gunnarsson, the founder of S2, will be joining CTI along with her entire team.
“I am very excited to combine forces with CTI and I know that we will be able to achieve great things together. Our principles, work ethic and expertise truly complement the CTI Team,” states Dr. Candace Gunnarsson, President of S2.
According to Lynn Fallon, Executive Vice President and President, Consulting Services at CTI, “The S2 team members are incredibly accomplished with top-ranked scientists, health economists, and statisticians, and will join Dr. William Irish, CTI’s Vice President of Health Outcomes and Biostatistics, as well as the rest of our team at CTI. We firmly believe that health outcomes and economics are critically important to both our biotechnology and pharmaceutical clients. This merger strengthens our service offerings from the early development stages of drugs and devices through Phase 3 and commercialization. Investors often require companies to build economic models to provide product valuation, even in early development. Health economics is also proving particularly important to the many orphan disease programs that CTI is leading.”
The terms of the acquisition were not disclosed. Plante Moran and Fifth Third Bank provided support to CTI, while Graydon, Head and Ritchey assisted S2.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.